Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of ramucirumab in persistent or recurrent ovarian, fallopian tube, or primary peritoneal carcinoma
2007-006717-17Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ramucirumab in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Eli Lilly and Company. Primary endpoints: Progression-free survival rate at 6 months and Objective response rate. Started Oct 2008; status: completed.
02
Drugs
ramucirumab
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2007-006717-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006717-17.